{
    "nct_id": "NCT04086745",
    "official_title": "A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis",
    "inclusion_criteria": "* Participants must have at least one of the following characteristics:\n\n  * Documented evidence of a VTE prior to this study\n  * At least 60 years of age\n  * A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²), or\n  * Age 50 to less than 60 years and BMI 25 to less than 30 kg/m²\n* Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drugs (DMARD) (synthetic or biologic)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participant must not have prior use of a Janus kinase (JAK) inhibitor or have received more than 1 prior TNF inhibitor that was:\n\n  * discontinued for IR (lack or loss of efficacy) for RA, or\n  * discontinued for intolerance (AE) when used for any indication\n* Participants must not be pregnant or breastfeeding\n* Participants must not have had more than one VTE\n* Participants must not have cancer\n* Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness\n* Participants must not have had a live vaccine within four weeks of study start\n* Participants must not have participated in any other clinical trial within four weeks of study start\n* Participants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year",
    "miscellaneous_criteria": ""
}